Prostatype Genomics AB Logo

Prostatype Genomics AB

Develops a genetic test that assesses prostate cancer aggressiveness to guide treatment.

PROGEN | ST

Overview

Corporate Details

ISIN(s):
SE0022574554 (+2 more)
LEI:
549300JO6MPCGPVHVU91
Country:
Sweden
Address:
Gustav III:s Boulevard 34, 169 73 Solna

Description

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test, Prostatype®. This test, also known as the Prostatype Genomic Classifier (PGC), is designed for patients with a localized prostate cancer diagnosis. It provides a comprehensive assessment of the cancer's aggressiveness, serving as a decision support tool for clinicians and patients to determine the most appropriate treatment path. The Prostatype® test system utilizes biopsy tissue obtained at diagnosis to analyze the expression of three specific genes. This genetic information is then combined with established clinical parameters (PSA, Gleason Score, and Tumor Stage) to calculate a P-score, which indicates the risk of cancer-specific mortality. The primary objective is to reduce the risks of over- and under-treatment, thereby enhancing patient quality of life and contributing to more efficient use of healthcare resources.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Prostatype Genomics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Prostatype Genomics AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Prostatype Genomics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

KAZIA THERAPEUTICS LTD Logo
Oncology-focused biotech developing targeted therapies for cancers with high unmet needs.
United States of America
KZIA
Keros Therapeutics, Inc. Logo
Develops protein therapeutics for disorders linked to TGF-β signaling.
United States of America
KROS
Kura Oncology, Inc. Logo
Clinical-stage biopharma company developing precision medicines for cancer treatment.
United States of America
KURA
Larimar Therapeutics, Inc. Logo
A clinical-stage biotech developing treatments for complex rare diseases.
United States of America
LRMR
Lexaria Bioscience Corp. Logo
A biotech company with a patented platform to improve oral drug delivery and absorption.
United States of America
LEXX
LigaChem Biosciences Inc. Logo
Clinical-stage biopharma developing ADCs, immuno-oncology drugs, and small molecules.
South Korea
141080
Linical Co., Ltd. Logo
A global CRO providing a full spectrum of drug development services for biopharma.
Japan
2183
Lipigon Pharmaceuticals AB Logo
A clinical-stage company developing therapeutics for lipid-related disorders.
Sweden
LPGO
Lipum AB Logo
Clinical-stage biopharma developing novel treatments for chronic inflammatory diseases.
Sweden
LIPUM
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Clinical-stage pharma company developing PP2A inhibitors to enhance cancer therapies.
United States of America
LIXT

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.